Ngā hua rapu kaituhi :: APM

1

PD-1 and PD-L1 antibodies in cancer: current status and future directions mā Arjun Vasant Balar, Jeffrey S. Weber

I whakaputaina 2017

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI mā Andrew B. Rosenkrantz, Kent Friedman, Fabio Ponzo, Roy A. Raad, Kimberly Jackson, William C. Huang, Arjun Vasant Balar

I whakaputaina 2016

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients mā Douglas M. Donnelly, Shirin Bajaj, Jae-Hong Yu, Miles Hsu, Arjun Vasant Balar, Anna C. Pavlick, Jeffrey S. Weber, Iman Osman, Judy Zhong

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma mā Brian Labadie, Ping Liu, Riyue Bao, Michael Crist, Ricardo Fernandes, Laura Ferreira, Scott Graupner, Andrew Poklepovic, Ignacio Durán, Saman Maleki Vareki, Arjun Vasant Balar, Jason J. Luke

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer mā Arjun Vasant Balar, Andrea B. Apolo, Irina Ostrovnaya, Svetlana Mironov, Alexia Iasonos, A. Trout, Ashley Marie Regazzi, Ilana Garcia-Grossman, David Gallagher, Matthew I. Milowsky, Dean F. Bajorin

I whakaputaina 2013

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status mā Petros Grivas, Elizabeth R. Plimack, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Joaquim Bellmunt, Thomas Powles, Noah M. Hahn, Ronald de Wit, Dean F. Bajorin, Misoo C. Ellison, Tara L. Frenkl, James Luke Godwin, Jacqueline Vuky

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Phase <scp>II</scp> study of everolimus in metastatic urothelial cancer mā Matthew I. Milowsky, Gopa Iyer, Ashley Marie Regazzi, Hikmat Al‐Ahmadie, Scott R. Gerst, Irina Ostrovnaya, Lan L. Gellert, Rana Kaplan, Ilana Garcia-Grossman, Deepa Pendse, Arjun Vasant Balar, Anne Marie C. Flaherty, A. Trout, David B. Solit, Dean F. Bajorin

I whakaputaina 2013

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study mā Arjun Vasant Balar, Joaquim Bellmunt, Peter H. O’Donnell, Daniel Castellano, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, Mary J. Savage, Rodolfo F. Perini, Stephen J. O’Keefe, Dean F. Bajorin

I whakaputaina 2016

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy mā Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Bradley A. McGregor, Elisabeth I. Heath, Evan Y. Yu, Matthew D. Galsky, Noah M. Hahn, Elaina M. Gartner, Juan Pinelli, Shang-Ying Liang, Amal Melhem‐Bertrandt, Daniel P. Petrylak

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer mā Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Savage, Xiao Fang, James Luke Godwin, Tara L. Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R. Plimack

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Somatic mutation of fibroblast growth factor receptor‐3 (<i>FGFR3</i>) defines a distinct morphological subtype of high‐grade urothelial carcinoma mā Hikmat Al‐Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy, Satish K. Tickoo, Samson W. Fine, Anuradha Gopalan, Ying‐Bei Chen, Arjun Vasant Balar, Jamie C. Riches, Bernard H. Bochner, Guido Dalbagni, Dean F. Bajorin, Victor E. Reuter, Matthew I. Milowsky, David B. Solit

I whakaputaina 2011

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhi... mā Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhi... mā Yohann Loriot, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, M. Sierecki, Hao Zhou, Petros Grivas, Philippe Barthélémy, Scott T. Tagawa

I whakaputaina 2024

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer mā Gopa Iyer, Hikmat Al‐Ahmadie, Nikolaus Schultz, Aphrothiti J. Hanrahan, Irina Ostrovnaya, Arjun Vasant Balar, Philip H. Kim, Oscar Lin, Nils Weinhold, Chris Sander, Emily C. Zabor, Manickam Janakiraman, Ilana Garcia-Grossman, Adriana Heguy, Agnès Viale, Bernard H. Bochner, Victor E. Reuter, Dean F. Bajorin, Matthew I. Milowsky, Barry S. Taylor, David B. Solit

I whakaputaina 2013

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer mā Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwénaëlle Gravis, Florence Joly, Joan Carles, Aude Fléchon, Pablo Maroto, Daniel P. Petrylak, Frédéric Rolland, Natalie Cook, Arjun Vasant Balar, Srikala S. Sridhar, Matthew D. Galsky, Petros Grivas, Alain Ravaud, Robert J. Jones, Jan Cosaert, Darren Hodgson, Iwanka Kozarewa, Richard Mather, Robert McEwen, Florence Mercier, Dónal Landers

I whakaputaina 2021

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up mā Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials mā Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel Ángel Climent, Daniel P. Petrylak, Jae‐Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O’Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun Vasant Balar, Daniel Castellano, Toni K. Choueiri, Stéphane Culine, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Rǎzvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicent... mā Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, Jose Luis Pérez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer

I whakaputaina 2016

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer mā Gopa Iyer, Arjun Vasant Balar, Matthew I. Milowsky, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, William C. Huang, Samir S. Taneja, Michael Woods, Irina Ostrovnaya, Hikmat Al‐Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Tracy L. Rose, William Y. Kim, Brooke Kania, Mariel Elena Boyd, C Cipolla, Ashley Marie Regazzi, Daniela Delbeau, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin

I whakaputaina 2018

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial mā Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, Jose Luis Pérez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin

I whakaputaina 2016

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: